GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » Shiller PE Ratio

CRSP (CRISPR Therapeutics AG) Shiller PE Ratio : (As of Jul. 08, 2025)


View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CRISPR Therapeutics AG Shiller PE Ratio Historical Data

The historical data trend for CRISPR Therapeutics AG's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Shiller PE Ratio Chart

CRISPR Therapeutics AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CRISPR Therapeutics AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CRISPR Therapeutics AG's Shiller PE Ratio

For the Biotechnology subindustry, CRISPR Therapeutics AG's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Shiller PE Ratio falls into.


;
;

CRISPR Therapeutics AG Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

CRISPR Therapeutics AG's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, CRISPR Therapeutics AG's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.58/107.7224*107.7224
=-1.580

Current CPI (Mar. 2025) = 107.7224.

CRISPR Therapeutics AG Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 0.000 100.704 0.000
201509 -0.217 99.785 -0.234
201512 -0.419 99.386 -0.454
201603 -0.288 99.475 -0.312
201606 -0.432 100.088 -0.465
201609 -0.370 99.604 -0.400
201612 0.430 99.380 0.466
201703 -0.540 100.040 -0.581
201706 -0.560 100.285 -0.602
201709 -0.620 100.254 -0.666
201712 0.010 100.213 0.011
201803 -0.620 100.836 -0.662
201806 -0.820 101.435 -0.871
201809 -1.070 101.246 -1.138
201812 -0.920 100.906 -0.982
201903 -0.930 101.571 -0.986
201906 -1.010 102.044 -1.066
201909 2.400 101.396 2.550
201912 0.510 101.063 0.544
202003 -1.150 101.048 -1.226
202006 -1.300 100.743 -1.390
202009 -1.320 100.585 -1.414
202012 -1.520 100.241 -1.633
202103 -1.510 100.800 -1.614
202106 9.440 101.352 10.033
202109 -1.670 101.533 -1.772
202112 -1.840 101.776 -1.948
202203 -2.320 103.205 -2.422
202206 -2.400 104.783 -2.467
202209 -2.240 104.835 -2.302
202212 -1.410 104.666 -1.451
202303 -0.670 106.245 -0.679
202306 -0.980 106.576 -0.991
202309 -1.410 106.570 -1.425
202312 1.130 106.461 1.143
202403 -1.430 107.355 -1.435
202406 -1.490 107.991 -1.486
202409 -1.010 107.468 -1.012
202412 -0.440 107.128 -0.442
202503 -1.580 107.722 -1.580

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CRISPR Therapeutics AG  (NAS:CRSP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


CRISPR Therapeutics AG Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CRISPR Therapeutics AG Business Description

Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Executives
Raju Prasad officer: Chief Financial Officer CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127
Samarth Kulkarni officer: Chief Business Officer C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
James R. Kasinger officer: General Counsel and Secretary C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139
John Greene director 51 LIME STREET, LONDON X0 EC3M 7DQ
Phuong Khanh Morrow officer: Chief Medical Officer C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139
Maria Fardis director C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Brendan Smith officer: Chief Financial Officer 29 HARTWELL AVENUE, LEXINGTON MA 02421
Michael John Tomsicek officer: Chief Financial Officer 28 OVERLOOK DRIVE, BEDFORD MA 01730
Bolzon Bradley J Phd director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Rodger Novak director, officer: Chief Executive Officer C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Harold Edward Fleming director C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Lawrence Otto Klein officer: Chief Business Officer C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139
Tony W Ho officer: See Remarks CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Douglas A Treco director 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Pablo J Cagnoni director ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080